Artesunate Derivatives as Anticancer Agents: Hybrid Designs and Emerging Therapeutic Strategies
ChemMedChem · 26.11.2026 · 21 (22)
DOI: 10.1002/cmdc.70577 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, online erschienen am 16.11.2026. Verfasst von Milica Selaković und 7 weiteren Autor:innen. Die Arbeit nennt 145 Literaturangaben. Gefördert von: Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja, Science Fund of the Republic of Serbia.
Abstract (Originalsprache)
Artesunate is a semisynthetic derivative of the natural product artemisinin, isolated from Artemisia annua and characterized by the biologically important endoperoxide bridge. Beyond its established use in malaria treatment, in recent decades, artesunate has attracted growing research interest as an anticancer agent. Despite encouraging preclinical results, clinical studies demonstrated only modest efficacy when artesunate was used as a single compound, due to its low bioavailability, toxicity, and unfavorable side effects. For this reason, artesunate derivatization has attracted significant attention, as the resulting derivatives often exhibit superior anticancer activity in both in vitro and in vivo studies compared with artesunate alone. This review offers a comprehensive overview of reported artesunate derivatives, structured into sections based on the type of molecule employed for derivatization and highlights the expanding research on their anticancer activity. Currently emerging strategies that include hybridization and nanocarrier‐based delivery systems which may accelerate the clinical translation of artesunate derivatives and harness their potential in anticancer drug discovery are also discussed. While significant progress has been made, a lot of the research field still remains underexplored.
Förderung
- Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja
- Science Fund of the Republic of Serbia
Zitieren
APA
Selaković, M., Koračak, L., Ajdačić, V., Nikolić, A. M., Selaković, Ž., Andrijević, A., Rodrigo, M. A. M., & Opsenica, I. M. (2026). Artesunate Derivatives as Anticancer Agents: Hybrid Designs and Emerging Therapeutic Strategies. ChemMedChem, 21(22). https://doi.org/10.1002/cmdc.70577
Vancouver
Selaković M, Koračak L, Ajdačić V, Nikolić AM, Selaković Ž, Andrijević A, et al. Artesunate Derivatives as Anticancer Agents: Hybrid Designs and Emerging Therapeutic Strategies. ChemMedChem. 2026;21(22). doi:10.1002/cmdc.70577
BibTeX
@article{Selakovi2026,
author = {Selaković, Milica and Koračak, Ljiljana and Ajdačić, Vladimir and Nikolić, Andrea M. and Selaković, Života and Andrijević, Ana and Rodrigo, Miguel Angel Merlos and Opsenica, Igor M.},
title = {Artesunate Derivatives as Anticancer Agents: Hybrid Designs and Emerging Therapeutic Strategies},
journal = {ChemMedChem},
year = {2026},
volume = {21},
number = {22},
doi = {10.1002/cmdc.70577}
}
EUVIMED